Business
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients Updated JANX007 data from Phase 1a dose escalation support initiation of Phase
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":"\n\nPhase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients\n\n\nUpdated JANX007 data from Phase 1a dose escalation support initiation of Phase 1b dose expansion\n\n\nEnrollment ongoing for JANX007 and JANX008\n\n\nUpdates on JANX007 and JANX008 expected in the second half of 2025\n\n\n$1.01 billion in cash, cash equivalents, and short-term investments at end of first quarter 2025\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.\n\n“We are proud to advance into the next phase of our clinical journey for JANX007 and begin treating patients in our Phase 1b expansion studies,” said David Campbell, Ph.D., President and CEO of Janux. “We also look forward to our first R&D Day where we will unveil previously undisclosed preclinical programs that utilize our expertise and platform technologies to address significant unmet medical needs.”\n\nRECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:\n\n\nInitiated first Phase 1b expansion study with JANX007 in taxane-naïve mCRPC patients.\n\nIn December 2024, Janux reported positive interim clinical data from the Phase 1a dose escalation portion of the trial in 16 metastatic castration-resistant prostate cancer (mCRPC) patients with a median of four prior lines of therapy. At that time, the median radiographic progression-free survival (rPFS) reported was 7.4 months for all 16 patients.* As of April 21, 2025, updated results** have been achieved in the same 16 patients supporting the initiation of the Phase 1b expansion studies:\n\n\n\nMedian rPFS of 7.5 months (n=16)\n\n\nMedian rPFS of 7.9 months for patients treated at 6mg and 9mg target doses (n=9)\n\n\n6-month rPFS of 65% (n=16)\n\n\n6-month rPFS of 78% for patients treated at 6mg and 9mg target doses (n=9)\n\n\nSafety data remained consistent with the December 2024 data disclosure (n=16)\n\n\n*8/16 patients were noted as in-progress in the December 2024 reported results.\n**rPFS results based upon Kaplan-Meier estimate.\n\nJanux selected 0.3...